Connor, Clark & Lunn Investment Management (CC&L)’s 10x Genomics TXG Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.9M	Buy	988,320 +49,912	+5%	+$1.31M	0.07%	241
2026 Q1	$19.9M	Buy	938,408 +228,829	+32%	+$4.57M	0.05%	317
2025 Q4	$11.6M	Buy	709,579 +392,106	+124%	+$5.92M	0.03%	426
2025 Q3	$3.71M	Buy	+317,473	New	+$4.14M	0.01%	666
2023 Q1	–	Sell	-25,085	Closed	-$914K	–	1461
2022 Q4	$914K	Buy	+25,085	New	+$820K	0.01%	728

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s TXG Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its 10x Genomics (TXG) stake by 5.3% in Q2 2026, buying an estimated $1.31M and bringing the position to 988,320 shares worth $37.9M. The position accounts for 0.07% of the portfolio, ranked #241.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TXG in Q4 2022 and has held it in 5 quarters since. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 988,320 shares of 10x Genomics worth $37.9M as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) bought 49,912 10x Genomics shares in Q2 2026, an estimated $1.31M.
10x Genomics made up 0.07% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #241 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in 10x Genomics in Q4 2022 and has held it in 5 quarters since.
393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.